| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | May'10 | May'09 | May'08 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||||
Net loss | |||||||||||
-182,602 | 407,807 | -154,175 | 3,030 | -2,056 | -66,453 | -104,026 | -1,153 | 73,609 | 62,870 | 26,022 | 25,399 |
Less: Loss from discontinued operations | |||||||||||
0 | 395,138 | 30,348 | -28,221 | - | - | - | - | - | - | - | - |
(Loss) income from continuing operations | |||||||||||
-182,602 | 12,669 | -184,523 | 31,251 | - | - | - | - | - | - | - | - |
Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||||||
Depreciation and amortization | |||||||||||
207,106 | 192,346 | 157,328 | 136,328 | 161,011 | 174,263 | 178,815 | 150,234 | 132,400 | 36,522 | 22,787 | 16,192 |
Operating right-of-use asset amortization | |||||||||||
22,534 | 0 | 0 | - | - | - | - | - | - | - | - | - |
Stock-based compensation expense | |||||||||||
38,982 | 34,638 | 36,540 | 37,093 | 34,663 | 39,254 | 37,010 | 39,126 | 40,752 | 14,849 | 5,770 | 2,208 |
Excess tax benefits from stock-based compensation | |||||||||||
- | - | - | - | 644 | 0 | 3,887 | 3,516 | 8,818 | 6,251 | 5,463 | 0 |
Write-off of unamortized deferred debt issuance costs - Netsmart | |||||||||||
- | - | - | - | 1,433 | 0 | - | - | - | - | - | - |
Provision for doubtful accounts | |||||||||||
- | - | - | - | - | - | - | - | - | - | 5,893 | 2,415 |
Deferred taxes | |||||||||||
37,970 | -4,144 | 10,228 | 4,520 | 2,206 | 56 | 43,880 | 12,780 | -33,395 | -31,562 | 1,194 | 1,952 |
Asset impairment charges | |||||||||||
10,837 | 58,166 | 0 | 4,650 | 1,544 | 2,390 | 11,454 | 11,101 | 0 | 0 | 15,876 | 0 |
Goodwill impairment charge | |||||||||||
25,700 | 13,466 | 0 | 0 | - | - | - | - | - | - | - | - |
Recovery of long-term investments | |||||||||||
651 | 15,487 | 165,290 | 0 | 0 | - | - | - | - | - | - | - |
Equity in net (loss) income of unconsolidated investments | |||||||||||
- | - | - | -7,501 | -2,100 | -398 | - | - | - | - | - | - |
Gain on sale of businesses, net | |||||||||||
0 | 172,258 | 0 | 0 | - | - | - | - | - | - | - | - |
Change in fair value of 1.25% call option and cash conversion option | |||||||||||
- | - | - | - | - | - | - | - | 0 | - | - | - |
Other loss (income), net | |||||||||||
-9,377 | 9,338 | -2,905 | -3,526 | 614 | -3,553 | -1,398 | -2,407 | -3,513 | 460 | 0 | 0 |
Loss on sale of prepackaged medications business | |||||||||||
- | - | - | - | - | - | - | - | - | - | -1,588 | 0 |
Changes in operating assets and liabilities (net of businesses acquired): | |||||||||||
Accounts receivable and contract assets, net | |||||||||||
13,273 | 109,134 | 95,189 | 8,918 | -3,215 | 14,644 | 7,705 | -45,978 | 30,731 | 26,798 | 30,303 | 11,289 |
Inventories | |||||||||||
- | - | - | - | - | - | - | - | - | - | -231 | 0 |
Prepaid expenses and other assets | |||||||||||
15,374 | 55,818 | -13,219 | -4,454 | -17,614 | 7,038 | 23,481 | 14,430 | 17,551 | 18,695 | 6,858 | 3,749 |
Other long-term assets | |||||||||||
- | - | - | - | - | - | - | - | - | - | - | 4,594 |
Accounts payable | |||||||||||
27,799 | -19,159 | -19,785 | 45,524 | -11,953 | -1,944 | 23,794 | 3,440 | -8,546 | 13,056 | -2,924 | -3,836 |
Accrued expenses | |||||||||||
141,407 | 40,484 | 10,131 | -2,774 | -22,974 | -22,767 | -4,552 | 3,397 | 8,581 | 14,775 | -2,036 | -2,781 |
Accrued compensation and benefits | |||||||||||
-32,471 | 13,440 | 18,717 | -10,514 | 10,257 | -29,544 | 33,482 | 13,101 | -14,766 | 709 | -7,740 | -8,391 |
Deferred revenue | |||||||||||
-94,353 | 58,010 | 112,684 | -11,418 | 20,372 | 33,109 | -1,573 | -16,591 | 57,606 | 18,092 | 14,577 | -5,703 |
Other liabilities | |||||||||||
-7,746 | 12,091 | 17,969 | 2,165 | -183 | -7,025 | -15,862 | 2,356 | -690 | -313 | -149 | 0 |
Operating leases | |||||||||||
-24,350 | 0 | 0 | - | - | - | - | - | - | - | - | - |
Net cash (used in) provided by operating activities - discontinued operations | |||||||||||
-30,000 | -21,343 | 54,357 | 34,656 | - | - | - | - | - | - | - | - |
Net cash (used in) provided by operating activities | |||||||||||
76,254 | 89,234 | 225,058 | 234,348 | 211,579 | 103,496 | 80,987 | 222,670 | 268,754 | 139,918 | 36,077 | 7,823 |
Cash flows from investing activities: | |||||||||||
Capital expenditures | |||||||||||
16,600 | 31,309 | 38,759 | 32,107 | 18,322 | 26,438 | 74,130 | 80,166 | 44,306 | 13,919 | -4,970 | -1,167 |
Capitalized software | |||||||||||
113,836 | 113,308 | 118,241 | 92,179 | 49,264 | 40,661 | 42,026 | 42,965 | 60,748 | 21,097 | -14,001 | 0 |
Sales and maturities of marketable securities and other investments | |||||||||||
- | - | - | - | - | 50 | 12,891 | 94 | 55 | 7,017 | 8,703 | 0 |
Cash paid for business acquisitions, net of cash acquired | |||||||||||
23,443 | 177,233 | 169,823 | 99,837 | 9,372 | 20,180 | 148,875 | 0 | 0 | - | - | - |
Cash received from sale of businesses, net | |||||||||||
0 | 807,764 | 0 | 0 | - | - | - | - | - | - | - | - |
Purchases of equity securities, other investments and related intangible assets, net | |||||||||||
7,191 | 16,934 | 5,606 | 21,185 | 215,786 | 21,544 | 0 | 0 | 12,900 | - | - | - |
Other proceeds from investing activities | |||||||||||
-14 | -54 | -215 | -37 | -3,778 | - | - | - | - | - | - | - |
Purchases of marketable securities and other investments | |||||||||||
- | - | - | - | - | - | - | - | - | 4,008 | 2,522 | 0 |
Proceeds received from sale of fixed assets | |||||||||||
- | - | - | - | - | 85 | 0 | 0 | 20,000 | 0 | 0 | - |
Change in restricted cash | |||||||||||
- | - | - | - | - | - | - | - | -2,225 | 0 | 0 | 0 |
Net cash acquired in merger with Eclipsys | |||||||||||
- | - | - | - | - | - | - | - | - | 0 | - | - |
Payment for acquisition of Allscripts | |||||||||||
- | - | - | - | - | - | - | - | - | - | 329,494 | 0 |
Net proceeds received from sale of building | |||||||||||
- | - | - | - | - | - | - | - | - | - | 6,450 | 0 |
Net proceeds received from sale of prepackaged medications business | |||||||||||
- | - | - | - | - | - | - | - | - | - | 8,000 | 0 |
Purchase of preferred shares in iMedica | |||||||||||
- | - | - | - | - | - | - | - | - | - | - | 8,000 |
Net cash used in investing activities - discontinued operations | |||||||||||
0 | -221,021 | -80,758 | -908,735 | - | - | - | - | - | - | - | - |
Net cash used in investing activities | |||||||||||
-161,056 | 469,034 | -332,214 | -245,271 | -288,966 | -108,688 | -252,140 | -123,037 | -95,674 | -32,007 | -262,106 | -9,167 |
Cash flows from financing activities: | |||||||||||
Proceeds from issuance 1.25% senior cash convertible notes, net of issuance costs | |||||||||||
- | - | - | - | - | - | 336,662 | 0 | 0 | - | - | - |
Purchase of call option related to 1.25% senior cash convertible notes | |||||||||||
- | - | - | - | - | - | 82,800 | 0 | 0 | - | - | - |
Proceeds from issuance of warrants, net of issuance costs | |||||||||||
- | - | - | - | - | - | 51,208 | 0 | 0 | - | - | - |
Proceeds from sale or issuance of common stock | |||||||||||
0 | 1,283 | 1,568 | 84 | 103,631 | 1,487 | 11,447 | 5,519 | 35,119 | 3,594 | 5,620 | - |
Proceeds from issuance of redeemable convertible preferred stock - Netsmart | |||||||||||
- | - | - | - | 0 | 0 | - | - | - | - | - | - |
Net proceeds from stock-based compensation activities | |||||||||||
- | - | - | - | - | - | - | - | - | - | - | 0 |
Proceeds from employee stock purchase plan, net | |||||||||||
- | - | - | - | - | - | - | - | - | - | - | 0 |
Excess tax benefits from stock-based compensation | |||||||||||
- | - | - | 1,014 | 644 | 0 | 3,887 | 3,516 | 8,818 | 6,251 | 5,463 | 0 |
Taxes paid related to net share settlement of equity awards | |||||||||||
7,286 | 9,466 | 7,269 | 8,204 | 7,062 | 10,400 | 9,732 | 10,292 | 11,456 | 0 | 0 | - |
Proceeds from issuance of 0.875% Convertible Senior Notes | |||||||||||
218,000 | 0 | 0 | - | - | - | - | - | - | - | - | - |
Payments for issuance costs on 0.875% Convertible Senior Notes | |||||||||||
5,445 | 0 | 0 | - | - | - | - | - | - | - | - | - |
Payments for capped call transaction on 0.875% Convertible Senior Notes | |||||||||||
17,222 | 0 | 0 | - | - | - | - | - | - | - | - | - |
Payments of lease obligations | |||||||||||
- | - | - | 370 | 598 | 455 | 458 | 822 | 1,427 | 1,510 | 1,340 | 1,571 |
Payments of acquisition financing obligations | |||||||||||
- | - | - | - | - | - | 29,671 | 0 | 0 | - | 2,734 | 0 |
Credit facility payments | |||||||||||
220,000 | 713,751 | 138,139 | 155,170 | 238,511 | 96,876 | 609,593 | 250,874 | 170,424 | 43,995 | 6,005 | 0 |
Credit facility borrowings, net of issuance costs | |||||||||||
279,241 | 430,843 | 325,001 | 250,000 | 284,161 | 101,964 | 460,983 | 324,010 | 47,193 | 0 | 0 | 0 |
Line of credit payments | |||||||||||
- | - | - | - | - | - | - | - | - | - | 41,915 | 113,824 |
Line of credit borrowings | |||||||||||
- | - | - | - | - | - | - | - | - | - | 38,683 | 113,821 |
Change in parent's net investment, including $330,000 received from Misys PLC | |||||||||||
- | - | - | - | - | - | - | - | - | - | 358,802 | 1,873 |
Repurchase of senior convertible notes | |||||||||||
- | - | - | - | - | - | - | - | - | - | 8,164 | 0 |
Repurchase of common stock | |||||||||||
111,460 | 138,928 | 12,077 | 121,241 | 0 | 0 | - | 225,961 | 51,462 | 0 | 51,547 | 0 |
Payment of acquisition and other financing obligations | |||||||||||
14,685 | 5,198 | 1,283 | 0 | 0 | - | - | - | - | - | - | - |
Purchases of subsidiary shares owned by non-controlling interest | |||||||||||
53,800 | 7,198 | 0 | 0 | - | - | - | - | - | - | - | - |
Proceeds from sales of subsidiary shares to non-controlling interest | |||||||||||
- | - | - | - | 0 | - | - | - | - | - | - | - |
Net cash provided by financing activities - discontinued operations | |||||||||||
0 | 149,432 | 30,784 | 899,158 | - | - | - | - | - | - | - | - |
Net cash provided (used in) by financing activities | |||||||||||
67,343 | -442,415 | 167,801 | 865,271 | 142,265 | -4,280 | 131,933 | -154,904 | -143,639 | -35,660 | 296,863 | 299 |
Effect of exchange rate changes on cash and cash equivalents | |||||||||||
203 | -624 | 860 | -532 | -1,178 | -309 | -1,782 | 1,474 | -1,091 | 0 | 0 | 0 |
Net increase (decrease) in cash and cash equivalents | |||||||||||
-47,256 | 22,297 | 65,888 | -20,263 | 63,700 | -9,781 | -41,002 | -53,797 | 28,350 | 72,251 | 70,834 | -1,045 |